Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.03. | NKGen Biotech, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 4 | SEC Filings | ||
13.03. | NKGen Biotech, Inc.: NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit | 1 | GlobeNewswire (USA) | ||
11.03. | NKGen Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
04.03. | NKGen Biotech wechselt nach Nasdaq-Delisting zum OTC-Markt | 6 | Investing.com Deutsch | ||
04.03. | NKGen Biotech shifts to OTC Markets after Nasdaq delisting | 5 | Investing.com | ||
NKGEN BIOTECH Aktie jetzt für 0€ handeln | |||||
04.03. | NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented | 341 | GlobeNewswire (Europe) | Trading commencing on the OTC Markets on March 5, 2025.Trading expected to continue under ticker symbol "NKGN" for common stock and "NKGNW" for warrants.NKGen Biotech, Inc. ("NKGen" or the "Company")... ► Artikel lesen | |
04.03. | NKGen Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
25.02. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
21.02. | NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program | 153 | GlobeNewswire (Europe) | SANTA ANA, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen | |
19.02. | NKGen Biotech: NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site | 3 | GlobeNewswire (USA) | ||
02.01. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.12.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.12.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
02.12.24 | NKGen Biotech, Inc.: NKGen Biotech Selected as Stalking Horse Bidder for NKMax | 1 | GlobeNewswire (USA) | ||
26.11.24 | NKGen Biotech faces Nasdaq compliance issue | 2 | Investing.com | ||
26.11.24 | NKGen Biotech, Inc.: NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel | 159 | GlobeNewswire (Europe) | SANTA ANA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "Notice") on November 20, 2024 from the... ► Artikel lesen | |
26.11.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
15.11.24 | NKGen Biotech, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
12.11.24 | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,183 | +6,27 % | Palatin's Phase 2 Obesity Study Shows Encouraging Appetite Suppression Data, Stock Up In Pre-Market | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN), Thursday announced results from its BMT-801 Phase 2 obesity study, which evaluated the co-administration of melanocortin 4 receptor or... ► Artikel lesen | |
BIOXXMED | 0,412 | +0,49 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,930 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,644 | +1,83 % | Ocugen Aktie: Leichte Erholung nach schwierigem Jahr | Trotz langfristiger Verluste halten Analysten an positiven Bewertungen für Ocugen fest. Die Gentherapie-Pipeline bleibt der zentrale Hoffnungsträger. Die Ocugen-Aktie zeigt heute eine leichte Erholung... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem unterzeichnet strategische Beteiligungsvereinbarung und gründet neues Joint Venture mit Promura GmbH | Vancouver, British Columbia - 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC:
SRBCF) ("Sirona"), ein Biotechnologieunternehmen, das auf kosmetische Inhaltsstoffe... ► Artikel lesen | |
BIO-GATE | 0,815 | -8,94 % | Bio-Gate startet Produkt-Launch für Tierpflege in den USA | Bio-Gate hat die Präsenz im nordamerikanischen Veterinärmarkt ausgebaut. Gemeinsam mit einem internationalen Anbieter bringt Bio-Gate neue Tierpflegeprodukte zur Haut-, Ohr- und Wundbehandlung in die... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,542 | -3,90 % | Blockbuster oder Übernahmefieber? Warum Novo Nordisk, Defence Therapeutics und Pfizer jetzt alle Blicke auf sich ziehen | Die Biotech- und Pharmabranche gleicht einem Schachbrett der Milliarden! Ein einziger Zug - ob Übernahme oder Zulassung - kann Aktienkurse in Stunden verdoppeln oder ganze Märkte neu ordnen. Während... ► Artikel lesen | |
VAXART | 0,312 | +2,64 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,058 | 0,00 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,270 | -1,46 % | Cellectar Biosciences: Multibagger mit Ansage? | Cellectar Biosciences (WKN: A3DQSD) heißt unsere Top-Spekulation der Stunde. Das auf Radiopharmaka gegen Krebs spezialisierte Biotechunternehmen konnte gestern eine wichtige Einigung mit der US-Gesundheitsbehörde... ► Artikel lesen | |
AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
IMMUNIC | 0,992 | +1,64 % | EQS-News: Immunic AG: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments | Issuer: Immunic AG
/ Key word(s): Financing
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
10.04.2025 / 19:00 CET/CEST
The... ► Artikel lesen | |
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,078 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
CEL-SCI | 0,246 | -2,92 % | CEL-SCI plant Zulassung für Krebsbehandlung in Saudi-Arabien zu beantragen |